Advertisements



CVG sets new cargo record; here"s which items are shipped most often

Cargo continues to boom at Cincinnati/Northern Kentucky International Airport, with the airport setting another all-time record for the amount of cargo flowing through in April......»»

Category: topSource: bizjournalsMay 24th, 2021

Why your PayPal money is on hold or pending, and how to resolve the issue

PayPal puts money on hold to help ensure the platform is safe to use for both buyers and sellers. There's a number of reasons why your PayPal money may be placed on hold, but there are a few solutions. Maskot/Getty Images PayPal puts money on hold to help ensure the platform is safe to use for both buyers and sellers. Your PayPal money might be on hold if you're a new seller or your account has been inactive. To help release funds faster, add tracking information to your orders or print a shipping label via PayPal. Visit Insider's Tech Reference library for more stories. PayPal is a convenient platform for small business owners to collect payment for their goods and services in a secure manner. Sometimes, PayPal will put funds on hold for up to 21 days to ensure there is enough money in your account should any issues arise with the order. There are several reasons why a payment may be on hold, and ways for sellers to expedite the release of funds. Here's everything you need to know.Table of Contents: Masthead StickyWhy does PayPal put payments on hold?PayPal notes that the company puts payments on hold to help ensure that the platform is safe and secure for both buyers and sellers. Although the money belongs to you, PayPal will temporarily keep you from accessing it to make sure there's enough money in your account to resolve issues like chargebacks or disputes. Funds are released when the buyer confirms that they received the item they ordered in the condition that was advertised.Some specific reasons why your payment might be on hold include:Your PayPal account has been inactive.The payment you received is unusual for your typical selling pattern.PayPal found an unusual change in selling price for a particular transaction.You're selling an item that customers may be dissatisfied with.You've only recently started selling items outside of eBay.Why is my payment on hold?There are a number of reasons for why funds could be placed on hold, including:You're new to selling. New sellers need to build up their buyer-seller credibility and history. Once you've established a successful transaction record, your status can change.You haven't sold anything in a long time. Similar to being a first-time seller, if you haven't sold an item in awhile, you'll need to rebuild your credibility.Customers filed formal complaints for a refund, dispute, or chargeback. If you've been flagged by multiple customers for various issues, PayPal may delay the availability of your funds. According to PayPal, the best way to remedy this is to work directly with buyers to ensure that issues are resolved as quickly as possible. To prevent complaints, be upfront about shipping costs, item condition, and return policy. You can also set up a customer service message to let customers know if an extreme incident - like a natural disaster in your area - is preventing you from shipping on time.You have a suspicious selling pattern. PayPal will flag an account that has unusual activity, including a higher than normal selling pattern or a distinct change in the type of items sold.You're selling riskier items. Examples of these kinds of items include tickets, gift cards, consumer electronics, computers, and travel packages - anything that is more expensive or event-related.When can I access my payment?As long as there aren't any issues with your transaction or account (like an undelivered package or a customer filing a dispute), PayPal will release your funds within 21 days.How can I access my money faster?There are some steps sellers can take to help release PayPal funds faster. These include:Add tracking: Use one of PayPal's approved shipping carriers, and PayPal will release the hold on funds one day after the courier confirms delivery.Print a USPS or UPS shipping label via PayPal: PayPal will track your package and release the hold on funds one day after the courier confirms delivery.Update the order status for services or intangible items: For items that aren't shipped, like e-books or knitting lessons, update the order status and PayPal will release funds in seven days.How to prevent the delay of fundsCheck your email: Review the email sent from PayPal (with the subject line "An important message about your PayPal balance") as well as the alert located in your Account Overview page. It will include information about why your funds aren't available and what you can do to avoid this in the future.Post real photos: Prevent refunds, disputes, and chargebacks from buyers by posting real photos of the items you're selling, including detailed and accurate descriptions, being transparent about shipping and handling times, costs, and methods, processing orders promptly, packing items with care so that they arrive in good condition, and being clear on your return policy upfront.Provide customer service: Do your best to communicate with and help your customers when they reach out. If you have a buyer dispute, work to resolve it as soon as possible.How to set up a PayPal account and link a bank account or credit cardIs PayPal secure? How the service protects your transactions, credit card data, and moreHow to delete your PayPal account, whether it's for business or personal useHow to remove your debit or credit card from PayPal in 5 simple stepsRead the original article on Business Insider.....»»

Category: smallbizSource: nytSep 24th, 2021

H. B. Fuller (FUL) Tops Q3 Earnings and Revenue Estimates

H. B. Fuller (FUL) delivered earnings and revenue surprises of 2.60% and 3.71%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock? H. B. Fuller (FUL) came out with quarterly earnings of $0.79 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.60%. A quarter ago, it was expected that this adhesives company would post earnings of $0.92 per share when it actually produced earnings of $0.94, delivering a surprise of 2.17%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.H. B. Fuller, which belongs to the Zacks Chemical - Specialty industry, posted revenues of $826.83 million for the quarter ended August 2021, surpassing the Zacks Consensus Estimate by 3.71%. This compares to year-ago revenues of $691.46 million. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.H. B. Fuller shares have added about 15.4% since the beginning of the year versus the S&P 500's gain of 15.9%.What's Next for H. B. Fuller?While H. B. Fuller has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for H. B. Fuller was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.06 on $841.19 million in revenues for the coming quarter and $3.49 on $3.19 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Chemical - Specialty is currently in the top 29% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report H. B. Fuller Company (FUL): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 22nd, 2021

KB Home (KBH) Q3 Earnings Surpass Estimates

KB Home (KBH) delivered earnings and revenue surprises of 2.50% and -5.98%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock? KB Home (KBH) came out with quarterly earnings of $1.64 per share, beating the Zacks Consensus Estimate of $1.60 per share. This compares to earnings of $0.83 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 2.50%. A quarter ago, it was expected that this homebuilder would post earnings of $1.29 per share when it actually produced earnings of $1.50, delivering a surprise of 16.28%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.KB Home, which belongs to the Zacks Building Products - Home Builders industry, posted revenues of $1.47 billion for the quarter ended August 2021, missing the Zacks Consensus Estimate by 5.98%. This compares to year-ago revenues of $999.01 million. The company has topped consensus revenue estimates just once over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.KB Home shares have added about 21.2% since the beginning of the year versus the S&P 500's gain of 15.9%.What's Next for KB Home?While KB Home has outperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for KB Home was unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.10 on $1.88 billion in revenues for the coming quarter and $6.23 on $6.02 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Building Products - Home Builders is currently in the top 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report KB Home (KBH): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 22nd, 2021

How to Protect Your Personal Finances When the Market is Down

Economic volatility is a good time for you to both reevaluate your personal finances and your investment risk tolerance. Just when we thought the pandemic was behind us, a surge in delta variant cases during the summer led to mask mandates and other restrictions being reinstated, and our old friend uncertainty—uncertainty about our jobs, our health, and our future—coming back into the picture.The “new normal” from last year has seemingly become our permanent reality, with many of us still working from home, jumping on Zoom ZM calls, baking too much banana bread, and watching a lot of television.Because of this, reviewing your personal finances is now more important than ever.To avoid going into panicked, stressed-out mode, start by figuring out your net worth. Calculate how much cash you have on hand, what’s in your investment portfolio(s), and your current debt load.By laying everything out on the table, from what you owe to how much money you’re able to bring in, you’ll be able to start to feel a little more in control.Another key step: start, or add to, an emergency savings fund.Despite the allure of online shopping, you may have found it easier to save your money this past year and a half, since bars, retail shops, restaurants, and movie theaters were all shuttered for a long period of time. Taking what you would have spent on dinner and a movie, for example, and putting it right into your piggy bank is a simple way to build up your fund.But if you really want to ramp up your savings, write down all of the things you think you’ll be able to live without for a while, like your morning Starbucks SBUX run or new fall clothes.The more luxuries or non-essential items you can cut from your budget, the more you’ll be able to easily save and the bigger (and quicker) your emergency fund will grow.Protecting Your Investment PortfolioLast year, we saw the U.S. economy come to a screeching halt due to nationwide lockdowns, and the recovery has been slow, steady, and a little bit rocky. But big tech stocks like Microsoft MSFT, Amazon AMZN, and Facebook FB have helped drive the major indexes to record highs, boosting investor sentiment across the board.The underlying economic data continues to improve bit by bit, and the markets are beginning to price in the Fed’s bond purchase tapering.But things could still get choppy—September has historically been a down month for the stock market, and the Dow and S&P 500 are in the red so far. One of the simplest ways to safeguard your investment portfolio in a volatile climate is diversification.Portfolio diversity doesn't just mean owning five stocks from five different sectors. It also means complementing stocks with bonds, real estate investments, hard assets and/or cash investments.The more diversified a portfolio is, the less vulnerable it is to broader macroeconomic events.Additionally, avoiding high beta stocks and sectors and favoring those that pay dividends can help your portfolio thrive during a downturn.Do You Cash Out?Moving your entire portfolio, or at least a portion, to cash is a thought that may have crossed your mind ever since the market meltdown in 2020.While most advisors will tell you to not do that, there is a scenario that you could consider if you are toying with the idea:If you are in a place where you don’t need to take on any more risk and you have all the money you’ll need for a good retirement, then moving to cash makes sense.But that’s a very rare situation.Overall, the amount of cash you should hold in your portfolio depends on what type of investor you are and where you are in your investment journey.For younger investors, there’s a good chance you can recover from any losses you experience now—history has shown that the market has risen after a downtown, surpassing past highs.For retirees, it’s a bit different. Financial advisors usually recommend having more cash on hand, but still keeping two to three years’ worth of investments you can rely on as part of your income.Something to always keep in mind, though, if you are thinking about or are tempted to cash out part of your portfolio is when you would you get back into the market. Timing the stock market is incredibly difficult, if not impossible, and you may miss out on dividend payments if you own stocks that pay those nice quarterly distributions.Final ThoughtsEconomic volatility is a good time for you to both reevaluate your personal finances and your investment risk tolerance.But always remember: reducing your exposure to risk is never a bad thing. You just have to figure out what is best for you and your investment horizon. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amazon.com, Inc. (AMZN): Free Stock Analysis Report Microsoft Corporation (MSFT): Free Stock Analysis Report Starbucks Corporation (SBUX): Free Stock Analysis Report Facebook, Inc. (FB): Free Stock Analysis Report Zoom Video Communications, Inc. (ZM): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 22nd, 2021

General Mills (GIS) Q1 Earnings and Revenues Top Estimates

General Mills (GIS) delivered earnings and revenue surprises of 12.50% and 4.31%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock? General Mills (GIS) came out with quarterly earnings of $0.99 per share, beating the Zacks Consensus Estimate of $0.88 per share. This compares to earnings of $1 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 12.50%. A quarter ago, it was expected that this maker of Cheerios cereal, Yoplait yogurt and other packaged foods would post earnings of $0.83 per share when it actually produced earnings of $0.91, delivering a surprise of 9.64%.Over the last four quarters, the company has surpassed consensus EPS estimates three times.General Mills, which belongs to the Zacks Food - Miscellaneous industry, posted revenues of $4.54 billion for the quarter ended August 2021, surpassing the Zacks Consensus Estimate by 4.31%. This compares to year-ago revenues of $4.36 billion. The company has topped consensus revenue estimates four times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.General Mills shares have lost about 1.3% since the beginning of the year versus the S&P 500's gain of 15.9%.What's Next for General Mills?While General Mills has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for General Mills was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $1.02 on $4.76 billion in revenues for the coming quarter and $3.75 on $17.94 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Food - Miscellaneous is currently in the bottom 31% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Infrastructure Stock Boom to Sweep America A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made. The only question is “Will you get into the right stocks early when their growth potential is greatest?” Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.Download FREE: How to Profit from Trillions on Spending for Infrastructure >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report General Mills, Inc. (GIS): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 22nd, 2021

The creative ways retailers are trying to sidestep shipping delays, from Home Depot flying in power tools to Walmart chartering smaller ships that can fit into tinier ports

As record numbers of cargo ships clog key ports, many retailers have been forced to scrap traditional strategies for much more expensive ones. ROSLAN RAHMAN/AFP via Getty Images A record number of container ships are causing backlogs in key US ports, causing shortages and price hikes. Major retailers like Walmart, Home Depot, and Lululemon have taken on extra costs to offset the shortages. The supply-chain snags threaten to cause further price hikes, as well as shutter more businesses. See more stories on Insider's business page. As record numbers of hulking cargo ships clog key ports and threaten the global supply chain, many retailers have been forced to find creative ways to overcome shortages and price hikes.From hoarding goods to chartering their own vessels and flying in products, retailers have been forced to quickly pivot, scrapping traditional strategies in favor of more expensive ones, as the companies prepare for an onslaught of holiday shopping.Last week, The Wall Street Journal reported that grocery stores had begun stock-piling Thanksgiving goods. Similarly, automotive and electronics companies have also been hoarding in-demand items like computer chips and video game consoles.Earlier this month, Lululemon told investors it is relying more heavily on air freight in order to avoid port congestion. Air shipments are significantly more expensive than transporting goods by sea. A $195 ocean shipment can cost $1,000 by air, according to Freightos. Last month, Walmart announced during an earnings call it was chartering its own ships to prepare for the holiday shopping season. By contracting with smaller logistic management companies, retailers can have more control over the movement of their goods, but they face a hefty price tag. Chartering a vessel can cost an average of $40,000 per day for a vessel carrying 3,000 20-foot containers - a rate which can add up to be even higher than record rates of $9,817.72 to ship a 40-foot container from Asia to the US, according to the Drewry World Container Index.Walmart has also taken to chartering smaller vessels in order to have the capacity to dock and unload at smaller ports where congestion is lower than key ports like those in Southern California that handle nearly half of US imports. Courtesy of Marine Exchange of Southern California Walmart is one of several retailers to begin chartering its own vessels in recent months. Ikea and Home Depot have also followed suit. In August, Ikea said it was shipping goods over private vessels, as well as purchasing its own shipping containers. Earlier in the summer, Home Depot told investors it was reserving its own ships, as well as snatching up merchandise on the spot market - a buying option that can cost as much as four times pre-established contract rates. Home Depot President and Chief Operating Officer Ted Decker said the company was also flying in "smaller, higher value items," like power tools on some occasions.Earlier this year, Peloton moved to prioritize logistical concerns as well, pumping $100 million into air and ocean freight deliveries due to long wait times for products. In January, Amazon expanded its transportation fleet by purchasing 11 Boeing 767 airliners to use as cargo planes. Amazon Ultimately, supply-chain snags are likely to add dominance to big-box retailers while cutting out smaller companies that don't have the extra funds to charter their own vessels or ship via cargo planes."Whenever we have a constrained supply like this it's always the big dogs that win," Douglas Kent, the executive vice president of strategy and alliances at the Association for Supply Chain Management, told Insider. "The smaller businesses just don't have the capital to keep up. They're already in survival mode. They're going to have to pass these costs on to customers and risk losing out to big-box retailers that can absorb the costs themselves. As a result, we will likely see the shuttering of more companies due to these ongoing issues."Read the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 21st, 2021

Jaxport sets new cargo record

Jaxport saw record volumes in 2019 of containers, autos and overall cargo. JAXPORT moved more than 1.338 million twenty-foot equivalent units, a 5 percent increase from 2018 - which was also a record year at the port. The port has seen four consec.....»»

Category: topSource: bizjournalsOct 25th, 2019

Port of Savannah sets monthly container record in August

The Port of Savannah set a record for containerized cargo last month, handling 437,750 twenty-foot equivalent container units (TEUs) at the Garden City Terminal, the Georgia Ports Authority reported Tuesday. That represents a 16.5% increase over Augus.....»»

Category: topSource: bizjournalsSep 24th, 2019

Port of Savannah sets containerized cargo record in October

The Port of Savannah set a record last month by moving 413,800 twenty-foot equivalent container units (TEUs) of cargo. Altogether during the first four months of fiscal 2019, containerized trade at Savannah was up 8 percent over the same period las.....»»

Category: topSource: bizjournalsNov 13th, 2018

Nucor sets records for earnings, revenue and steel shipments in 2018

Nucor Corp. reports 2018 earnings of $2.36 billion, or $7.42 per diluted share, on sales that totaled $25.1 billion. “We posted record earnings per share and record revenue, and we shipped a record amount of steel,” says Nucor CEO John Ferriola. â.....»»

Category: topSource: bizjournalsJan 29th, 2019

"Damn You To Hell, You Will Not Destroy America" - Here Is The "Spartacus COVID Letter" That"s Gone Viral

"Damn You To Hell, You Will Not Destroy America" - Here Is The 'Spartacus COVID Letter' That's Gone Viral Via The Automatic Earth blog, This is an anonymously posted document by someone who calls themselves Spartacus. Because it’s anonymous, I can’t contact them to ask for permission to publish. So I hesitated for a while, but it’s simply the best document I’ve seen on Covid, vaccines, etc. Whoever Spartacus is, they have a very elaborate knowledge in “the field”. If you want to know a lot more about the no. 1 issue in the world today, read it. And don’t worry if you don’t understand every single word, neither do I. But I learned a lot. The original PDF doc is here: Covid19 – The Spartacus Letter Hello, My name is Spartacus, and I’ve had enough. We have been forced to watch America and the Free World spin into inexorable decline due to a biowarfare attack. We, along with countless others, have been victimized and gaslit by propaganda and psychological warfare operations being conducted by an unelected, unaccountable Elite against the American people and our allies. Our mental and physical health have suffered immensely over the course of the past year and a half. We have felt the sting of isolation, lockdown, masking, quarantines, and other completely nonsensical acts of healthcare theater that have done absolutely nothing to protect the health or wellbeing of the public from the ongoing COVID-19 pandemic. Now, we are watching the medical establishment inject literal poison into millions of our fellow Americans without so much as a fight. We have been told that we will be fired and denied our livelihoods if we refuse to vaccinate. This was the last straw. We have spent thousands of hours analyzing leaked footage from Wuhan, scientific papers from primary sources, as well as the paper trails left by the medical establishment. What we have discovered would shock anyone to their core. First, we will summarize our findings, and then, we will explain them in detail. References will be placed at the end. Summary: COVID-19 is a blood and blood vessel disease. SARS-CoV-2 infects the lining of human blood vessels, causing them to leak into the lungs. Current treatment protocols (e.g. invasive ventilation) are actively harmful to patients, accelerating oxidative stress and causing severe VILI (ventilator-induced lung injuries). The continued use of ventilators in the absence of any proven medical benefit constitutes mass murder. Existing countermeasures are inadequate to slow the spread of what is an aerosolized and potentially wastewater-borne virus, and constitute a form of medical theater. Various non-vaccine interventions have been suppressed by both the media and the medical establishment in favor of vaccines and expensive patented drugs. The authorities have denied the usefulness of natural immunity against COVID-19, despite the fact that natural immunity confers protection against all of the virus’s proteins, and not just one. Vaccines will do more harm than good. The antigen that these vaccines are based on, SARS-CoV- 2 Spike, is a toxic protein. SARS-CoV-2 may have ADE, or antibody-dependent enhancement; current antibodies may not neutralize future strains, but instead help them infect immune cells. Also, vaccinating during a pandemic with a leaky vaccine removes the evolutionary pressure for a virus to become less lethal. There is a vast and appalling criminal conspiracy that directly links both Anthony Fauci and Moderna to the Wuhan Institute of Virology. COVID-19 vaccine researchers are directly linked to scientists involved in brain-computer interface (“neural lace”) tech, one of whom was indicted for taking grant money from China. Independent researchers have discovered mysterious nanoparticles inside the vaccines that are not supposed to be present. The entire pandemic is being used as an excuse for a vast political and economic transformation of Western society that will enrich the already rich and turn the rest of us into serfs and untouchables. COVID-19 Pathophysiology and Treatments: COVID-19 is not a viral pneumonia. It is a viral vascular endotheliitis and attacks the lining of blood vessels, particularly the small pulmonary alveolar capillaries, leading to endothelial cell activation and sloughing, coagulopathy, sepsis, pulmonary edema, and ARDS-like symptoms. This is a disease of the blood and blood vessels. The circulatory system. Any pneumonia that it causes is secondary to that. In severe cases, this leads to sepsis, blood clots, and multiple organ failure, including hypoxic and inflammatory damage to various vital organs, such as the brain, heart, liver, pancreas, kidneys, and intestines. Some of the most common laboratory findings in COVID-19 are elevated D-dimer, elevated prothrombin time, elevated C-reactive protein, neutrophilia, lymphopenia, hypocalcemia, and hyperferritinemia, essentially matching a profile of coagulopathy and immune system hyperactivation/immune cell exhaustion. COVID-19 can present as almost anything, due to the wide tropism of SARS-CoV-2 for various tissues in the body’s vital organs. While its most common initial presentation is respiratory illness and flu-like symptoms, it can present as brain inflammation, gastrointestinal disease, or even heart attack or pulmonary embolism. COVID-19 is more severe in those with specific comorbidities, such as obesity, diabetes, and hypertension. This is because these conditions involve endothelial dysfunction, which renders the circulatory system more susceptible to infection and injury by this particular virus. The vast majority of COVID-19 cases are mild and do not cause significant disease. In known cases, there is something known as the 80/20 rule, where 80% of cases are mild and 20% are severe or critical. However, this ratio is only correct for known cases, not all infections. The number of actual infections is much, much higher. Consequently, the mortality and morbidity rate is lower. However, COVID-19 spreads very quickly, meaning that there are a significant number of severely-ill and critically-ill patients appearing in a short time frame. In those who have critical COVID-19-induced sepsis, hypoxia, coagulopathy, and ARDS, the most common treatments are intubation, injected corticosteroids, and blood thinners. This is not the correct treatment for COVID-19. In severe hypoxia, cellular metabolic shifts cause ATP to break down into hypoxanthine, which, upon the reintroduction of oxygen, causes xanthine oxidase to produce tons of highly damaging radicals that attack tissue. This is called ischemia-reperfusion injury, and it’s why the majority of people who go on a ventilator are dying. In the mitochondria, succinate buildup due to sepsis does the same exact thing; when oxygen is reintroduced, it makes superoxide radicals. Make no mistake, intubation will kill people who have COVID-19. The end-stage of COVID-19 is severe lipid peroxidation, where fats in the body start to “rust” due to damage by oxidative stress. This drives autoimmunity. Oxidized lipids appear as foreign objects to the immune system, which recognizes and forms antibodies against OSEs, or oxidation-specific epitopes. Also, oxidized lipids feed directly into pattern recognition receptors, triggering even more inflammation and summoning even more cells of the innate immune system that release even more destructive enzymes. This is similar to the pathophysiology of Lupus. COVID-19’s pathology is dominated by extreme oxidative stress and neutrophil respiratory burst, to the point where hemoglobin becomes incapable of carrying oxygen due to heme iron being stripped out of heme by hypochlorous acid. No amount of supplemental oxygen can oxygenate blood that chemically refuses to bind O2. The breakdown of the pathology is as follows: SARS-CoV-2 Spike binds to ACE2. Angiotensin Converting Enzyme 2 is an enzyme that is part of the renin-angiotensin-aldosterone system, or RAAS. The RAAS is a hormone control system that moderates fluid volume in the body and in the bloodstream (i.e. osmolarity) by controlling salt retention and excretion. This protein, ACE2, is ubiquitous in every part of the body that interfaces with the circulatory system, particularly in vascular endothelial cells and pericytes, brain astrocytes, renal tubules and podocytes, pancreatic islet cells, bile duct and intestinal epithelial cells, and the seminiferous ducts of the testis, all of which SARS-CoV-2 can infect, not just the lungs. SARS-CoV-2 infects a cell as follows: SARS-CoV-2 Spike undergoes a conformational change where the S1 trimers flip up and extend, locking onto ACE2 bound to the surface of a cell. TMPRSS2, or transmembrane protease serine 2, comes along and cuts off the heads of the Spike, exposing the S2 stalk-shaped subunit inside. The remainder of the Spike undergoes a conformational change that causes it to unfold like an extension ladder, embedding itself in the cell membrane. Then, it folds back upon itself, pulling the viral membrane and the cell membrane together. The two membranes fuse, with the virus’s proteins migrating out onto the surface of the cell. The SARS-CoV-2 nucleocapsid enters the cell, disgorging its genetic material and beginning the viral replication process, hijacking the cell’s own structures to produce more virus. SARS-CoV-2 Spike proteins embedded in a cell can actually cause human cells to fuse together, forming syncytia/MGCs (multinuclear giant cells). They also have other pathogenic, harmful effects. SARS-CoV- 2’s viroporins, such as its Envelope protein, act as calcium ion channels, introducing calcium into infected cells. The virus suppresses the natural interferon response, resulting in delayed inflammation. SARS-CoV-2 N protein can also directly activate the NLRP3 inflammasome. Also, it suppresses the Nrf2 antioxidant pathway. The suppression of ACE2 by binding with Spike causes a buildup of bradykinin that would otherwise be broken down by ACE2. This constant calcium influx into the cells results in (or is accompanied by) noticeable hypocalcemia, or low blood calcium, especially in people with Vitamin D deficiencies and pre-existing endothelial dysfunction. Bradykinin upregulates cAMP, cGMP, COX, and Phospholipase C activity. This results in prostaglandin release and vastly increased intracellular calcium signaling, which promotes highly aggressive ROS release and ATP depletion. NADPH oxidase releases superoxide into the extracellular space. Superoxide radicals react with nitric oxide to form peroxynitrite. Peroxynitrite reacts with the tetrahydrobiopterin cofactor needed by endothelial nitric oxide synthase, destroying it and “uncoupling” the enzymes, causing nitric oxide synthase to synthesize more superoxide instead. This proceeds in a positive feedback loop until nitric oxide bioavailability in the circulatory system is depleted. Dissolved nitric oxide gas produced constantly by eNOS serves many important functions, but it is also antiviral against SARS-like coronaviruses, preventing the palmitoylation of the viral Spike protein and making it harder for it to bind to host receptors. The loss of NO allows the virus to begin replicating with impunity in the body. Those with endothelial dysfunction (i.e. hypertension, diabetes, obesity, old age, African-American race) have redox equilibrium issues to begin with, giving the virus an advantage. Due to the extreme cytokine release triggered by these processes, the body summons a great deal of neutrophils and monocyte-derived alveolar macrophages to the lungs. Cells of the innate immune system are the first-line defenders against pathogens. They work by engulfing invaders and trying to attack them with enzymes that produce powerful oxidants, like SOD and MPO. Superoxide dismutase takes superoxide and makes hydrogen peroxide, and myeloperoxidase takes hydrogen peroxide and chlorine ions and makes hypochlorous acid, which is many, many times more reactive than sodium hypochlorite bleach. Neutrophils have a nasty trick. They can also eject these enzymes into the extracellular space, where they will continuously spit out peroxide and bleach into the bloodstream. This is called neutrophil extracellular trap formation, or, when it becomes pathogenic and counterproductive, NETosis. In severe and critical COVID-19, there is actually rather severe NETosis. Hypochlorous acid building up in the bloodstream begins to bleach the iron out of heme and compete for O2 binding sites. Red blood cells lose the ability to transport oxygen, causing the sufferer to turn blue in the face. Unliganded iron, hydrogen peroxide, and superoxide in the bloodstream undergo the Haber- Weiss and Fenton reactions, producing extremely reactive hydroxyl radicals that violently strip electrons from surrounding fats and DNA, oxidizing them severely. This condition is not unknown to medical science. The actual name for all of this is acute sepsis. We know this is happening in COVID-19 because people who have died of the disease have noticeable ferroptosis signatures in their tissues, as well as various other oxidative stress markers such as nitrotyrosine, 4-HNE, and malondialdehyde. When you intubate someone with this condition, you are setting off a free radical bomb by supplying the cells with O2. It’s a catch-22, because we need oxygen to make Adenosine Triphosphate (that is, to live), but O2 is also the precursor of all these damaging radicals that lead to lipid peroxidation. The correct treatment for severe COVID-19 related sepsis is non-invasive ventilation, steroids, and antioxidant infusions. Most of the drugs repurposed for COVID-19 that show any benefit whatsoever in rescuing critically-ill COVID-19 patients are antioxidants. N-acetylcysteine, melatonin, fluvoxamine, budesonide, famotidine, cimetidine, and ranitidine are all antioxidants. Indomethacin prevents iron- driven oxidation of arachidonic acid to isoprostanes. There are powerful antioxidants such as apocynin that have not even been tested on COVID-19 patients yet which could defang neutrophils, prevent lipid peroxidation, restore endothelial health, and restore oxygenation to the tissues. Scientists who know anything about pulmonary neutrophilia, ARDS, and redox biology have known or surmised much of this since March 2020. In April 2020, Swiss scientists confirmed that COVID-19 was a vascular endotheliitis. By late 2020, experts had already concluded that COVID-19 causes a form of viral sepsis. They also know that sepsis can be effectively treated with antioxidants. None of this information is particularly new, and yet, for the most part, it has not been acted upon. Doctors continue to use damaging intubation techniques with high PEEP settings despite high lung compliance and poor oxygenation, killing an untold number of critically ill patients with medical malpractice. Because of the way they are constructed, Randomized Control Trials will never show any benefit for any antiviral against COVID-19. Not Remdesivir, not Kaletra, not HCQ, and not Ivermectin. The reason for this is simple; for the patients that they have recruited for these studies, such as Oxford’s ludicrous RECOVERY study, the intervention is too late to have any positive effect. The clinical course of COVID-19 is such that by the time most people seek medical attention for hypoxia, their viral load has already tapered off to almost nothing. If someone is about 10 days post-exposure and has already been symptomatic for five days, there is hardly any virus left in their bodies, only cellular damage and derangement that has initiated a hyperinflammatory response. It is from this group that the clinical trials for antivirals have recruited, pretty much exclusively. In these trials, they give antivirals to severely ill patients who have no virus in their bodies, only a delayed hyperinflammatory response, and then absurdly claim that antivirals have no utility in treating or preventing COVID-19. These clinical trials do not recruit people who are pre-symptomatic. They do not test pre-exposure or post-exposure prophylaxis. This is like using a defibrillator to shock only flatline, and then absurdly claiming that defibrillators have no medical utility whatsoever when the patients refuse to rise from the dead. The intervention is too late. These trials for antivirals show systematic, egregious selection bias. They are providing a treatment that is futile to the specific cohort they are enrolling. India went against the instructions of the WHO and mandated the prophylactic usage of Ivermectin. They have almost completely eradicated COVID-19. The Indian Bar Association of Mumbai has brought criminal charges against WHO Chief Scientist Dr. Soumya Swaminathan for recommending against the use of Ivermectin. Ivermectin is not “horse dewormer”. Yes, it is sold in veterinary paste form as a dewormer for animals. It has also been available in pill form for humans for decades, as an antiparasitic drug. The media have disingenuously claimed that because Ivermectin is an antiparasitic drug, it has no utility as an antivirus. This is incorrect. Ivermectin has utility as an antiviral. It blocks importin, preventing nuclear import, effectively inhibiting viral access to cell nuclei. Many drugs currently on the market have multiple modes of action. Ivermectin is one such drug. It is both antiparasitic and antiviral. In Bangladesh, Ivermectin costs $1.80 for an entire 5-day course. Remdesivir, which is toxic to the liver, costs $3,120 for a 5-day course of the drug. Billions of dollars of utterly useless Remdesivir were sold to our governments on the taxpayer’s dime, and it ended up being totally useless for treating hyperinflammatory COVID-19. The media has hardly even covered this at all. The opposition to the use of generic Ivermectin is not based in science. It is purely financially and politically-motivated. An effective non-vaccine intervention would jeopardize the rushed FDA approval of patented vaccines and medicines for which the pharmaceutical industry stands to rake in billions upon billions of dollars in sales on an ongoing basis. The majority of the public are scientifically illiterate and cannot grasp what any of this even means, thanks to a pathetic educational system that has miseducated them. You would be lucky to find 1 in 100 people who have even the faintest clue what any of this actually means. COVID-19 Transmission: COVID-19 is airborne. The WHO carried water for China by claiming that the virus was only droplet- borne. Our own CDC absurdly claimed that it was mostly transmitted by fomite-to-face contact, which, given its rapid spread from Wuhan to the rest of the world, would have been physically impossible. The ridiculous belief in fomite-to-face being a primary mode of transmission led to the use of surface disinfection protocols that wasted time, energy, productivity, and disinfectant. The 6-foot guidelines are absolutely useless. The minimum safe distance to protect oneself from an aerosolized virus is to be 15+ feet away from an infected person, no closer. Realistically, no public transit is safe. Surgical masks do not protect you from aerosols. The virus is too small and the filter media has too large of gaps to filter it out. They may catch respiratory droplets and keep the virus from being expelled by someone who is sick, but they do not filter a cloud of infectious aerosols if someone were to walk into said cloud. The minimum level of protection against this virus is quite literally a P100 respirator, a PAPR/CAPR, or a 40mm NATO CBRN respirator, ideally paired with a full-body tyvek or tychem suit, gloves, and booties, with all the holes and gaps taped. Live SARS-CoV-2 may potentially be detected in sewage outflows, and there may be oral-fecal transmission. During the SARS outbreak in 2003, in the Amoy Gardens incident, hundreds of people were infected by aerosolized fecal matter rising from floor drains in their apartments. COVID-19 Vaccine Dangers: The vaccines for COVID-19 are not sterilizing and do not prevent infection or transmission. They are “leaky” vaccines. This means they remove the evolutionary pressure on the virus to become less lethal. It also means that the vaccinated are perfect carriers. In other words, those who are vaccinated are a threat to the unvaccinated, not the other way around. All of the COVID-19 vaccines currently in use have undergone minimal testing, with highly accelerated clinical trials. Though they appear to limit severe illness, the long-term safety profile of these vaccines remains unknown. Some of these so-called “vaccines” utilize an untested new technology that has never been used in vaccines before. Traditional vaccines use weakened or killed virus to stimulate an immune response. The Moderna and Pfizer-BioNTech vaccines do not. They are purported to consist of an intramuscular shot containing a suspension of lipid nanoparticles filled with messenger RNA. The way they generate an immune response is by fusing with cells in a vaccine recipient’s shoulder, undergoing endocytosis, releasing their mRNA cargo into those cells, and then utilizing the ribosomes in those cells to synthesize modified SARS-CoV-2 Spike proteins in-situ. These modified Spike proteins then migrate to the surface of the cell, where they are anchored in place by a transmembrane domain. The adaptive immune system detects the non-human viral protein being expressed by these cells, and then forms antibodies against that protein. This is purported to confer protection against the virus, by training the adaptive immune system to recognize and produce antibodies against the Spike on the actual virus. The J&J and AstraZeneca vaccines do something similar, but use an adenovirus vector for genetic material delivery instead of a lipid nanoparticle. These vaccines were produced or validated with the aid of fetal cell lines HEK-293 and PER.C6, which people with certain religious convictions may object strongly to. SARS-CoV-2 Spike is a highly pathogenic protein on its own. It is impossible to overstate the danger presented by introducing this protein into the human body. It is claimed by vaccine manufacturers that the vaccine remains in cells in the shoulder, and that SARS- CoV-2 Spike produced and expressed by these cells from the vaccine’s genetic material is harmless and inert, thanks to the insertion of prolines in the Spike sequence to stabilize it in the prefusion conformation, preventing the Spike from becoming active and fusing with other cells. However, a pharmacokinetic study from Japan showed that the lipid nanoparticles and mRNA from the Pfizer vaccine did not stay in the shoulder, and in fact bioaccumulated in many different organs, including the reproductive organs and adrenal glands, meaning that modified Spike is being expressed quite literally all over the place. These lipid nanoparticles may trigger anaphylaxis in an unlucky few, but far more concerning is the unregulated expression of Spike in various somatic cell lines far from the injection site and the unknown consequences of that. Messenger RNA is normally consumed right after it is produced in the body, being translated into a protein by a ribosome. COVID-19 vaccine mRNA is produced outside the body, long before a ribosome translates it. In the meantime, it could accumulate damage if inadequately preserved. When a ribosome attempts to translate a damaged strand of mRNA, it can become stalled. When this happens, the ribosome becomes useless for translating proteins because it now has a piece of mRNA stuck in it, like a lace card in an old punch card reader. The whole thing has to be cleaned up and new ribosomes synthesized to replace it. In cells with low ribosome turnover, like nerve cells, this can lead to reduced protein synthesis, cytopathic effects, and neuropathies. Certain proteins, including SARS-CoV-2 Spike, have proteolytic cleavage sites that are basically like little dotted lines that say “cut here”, which attract a living organism’s own proteases (essentially, molecular scissors) to cut them. There is a possibility that S1 may be proteolytically cleaved from S2, causing active S1 to float away into the bloodstream while leaving the S2 “stalk” embedded in the membrane of the cell that expressed the protein. SARS-CoV-2 Spike has a Superantigenic region (SAg), which may promote extreme inflammation. Anti-Spike antibodies were found in one study to function as autoantibodies and attack the body’s own cells. Those who have been immunized with COVID-19 vaccines have developed blood clots, myocarditis, Guillain-Barre Syndrome, Bell’s Palsy, and multiple sclerosis flares, indicating that the vaccine promotes autoimmune reactions against healthy tissue. SARS-CoV-2 Spike does not only bind to ACE2. It was suspected to have regions that bind to basigin, integrins, neuropilin-1, and bacterial lipopolysaccharides as well. SARS-CoV-2 Spike, on its own, can potentially bind any of these things and act as a ligand for them, triggering unspecified and likely highly inflammatory cellular activity. SARS-CoV-2 Spike contains an unusual PRRA insert that forms a furin cleavage site. Furin is a ubiquitous human protease, making this an ideal property for the Spike to have, giving it a high degree of cell tropism. No wild-type SARS-like coronaviruses related to SARS-CoV-2 possess this feature, making it highly suspicious, and perhaps a sign of human tampering. SARS-CoV-2 Spike has a prion-like domain that enhances its infectiousness. The Spike S1 RBD may bind to heparin-binding proteins and promote amyloid aggregation. In humans, this could lead to Parkinson’s, Lewy Body Dementia, premature Alzheimer’s, or various other neurodegenerative diseases. This is very concerning because SARS-CoV-2 S1 is capable of injuring and penetrating the blood-brain barrier and entering the brain. It is also capable of increasing the permeability of the blood-brain barrier to other molecules. SARS-CoV-2, like other betacoronaviruses, may have Dengue-like ADE, or antibody-dependent enhancement of disease. For those who aren’t aware, some viruses, including betacoronaviruses, have a feature called ADE. There is also something called Original Antigenic Sin, which is the observation that the body prefers to produce antibodies based on previously-encountered strains of a virus over newly- encountered ones. In ADE, antibodies from a previous infection become non-neutralizing due to mutations in the virus’s proteins. These non-neutralizing antibodies then act as trojan horses, allowing live, active virus to be pulled into macrophages through their Fc receptor pathways, allowing the virus to infect immune cells that it would not have been able to infect before. This has been known to happen with Dengue Fever; when someone gets sick with Dengue, recovers, and then contracts a different strain, they can get very, very ill. If someone is vaccinated with mRNA based on the Spike from the initial Wuhan strain of SARS-CoV-2, and then they become infected with a future, mutated strain of the virus, they may become severely ill. In other words, it is possible for vaccines to sensitize someone to disease. There is a precedent for this in recent history. Sanofi’s Dengvaxia vaccine for Dengue failed because it caused immune sensitization in people whose immune systems were Dengue-naive. In mice immunized against SARS-CoV and challenged with the virus, a close relative of SARS-CoV-2, they developed immune sensitization, Th2 immunopathology, and eosinophil infiltration in their lungs. We have been told that SARS-CoV-2 mRNA vaccines cannot be integrated into the human genome, because messenger RNA cannot be turned back into DNA. This is false. There are elements in human cells called LINE-1 retrotransposons, which can indeed integrate mRNA into a human genome by endogenous reverse transcription. Because the mRNA used in the vaccines is stabilized, it hangs around in cells longer, increasing the chances for this to happen. If the gene for SARS-CoV-2 Spike is integrated into a portion of the genome that is not silent and actually expresses a protein, it is possible that people who take this vaccine may continuously express SARS-CoV-2 Spike from their somatic cells for the rest of their lives. By inoculating people with a vaccine that causes their bodies to produce Spike in-situ, they are being inoculated with a pathogenic protein. A toxin that may cause long-term inflammation, heart problems, and a raised risk of cancers. In the long-term, it may also potentially lead to premature neurodegenerative disease. Absolutely nobody should be compelled to take this vaccine under any circumstances, and in actual fact, the vaccination campaign must be stopped immediately. COVID-19 Criminal Conspiracy: The vaccine and the virus were made by the same people. In 2014, there was a moratorium on SARS gain-of-function research that lasted until 2017. This research was not halted. Instead, it was outsourced, with the federal grants being laundered through NGOs. Ralph Baric is a virologist and SARS expert at UNC Chapel Hill in North Carolina. This is who Anthony Fauci was referring to when he insisted, before Congress, that if any gain-of-function research was being conducted, it was being conducted in North Carolina. This was a lie. Anthony Fauci lied before Congress. A felony. Ralph Baric and Shi Zhengli are colleagues and have co-written papers together. Ralph Baric mentored Shi Zhengli in his gain-of-function manipulation techniques, particularly serial passage, which results in a virus that appears as if it originated naturally. In other words, deniable bioweapons. Serial passage in humanized hACE2 mice may have produced something like SARS-CoV-2. The funding for the gain-of-function research being conducted at the Wuhan Institute of Virology came from Peter Daszak. Peter Daszak runs an NGO called EcoHealth Alliance. EcoHealth Alliance received millions of dollars in grant money from the National Institutes of Health/National Institute of Allergy and Infectious Diseases (that is, Anthony Fauci), the Defense Threat Reduction Agency (part of the US Department of Defense), and the United States Agency for International Development. NIH/NIAID contributed a few million dollars, and DTRA and USAID each contributed tens of millions of dollars towards this research. Altogether, it was over a hundred million dollars. EcoHealth Alliance subcontracted these grants to the Wuhan Institute of Virology, a lab in China with a very questionable safety record and poorly trained staff, so that they could conduct gain-of-function research, not in their fancy P4 lab, but in a level-2 lab where technicians wore nothing more sophisticated than perhaps a hairnet, latex gloves, and a surgical mask, instead of the bubble suits used when working with dangerous viruses. Chinese scientists in Wuhan reported being routinely bitten and urinated on by laboratory animals. Why anyone would outsource this dangerous and delicate work to the People’s Republic of China, a country infamous for industrial accidents and massive explosions that have claimed hundreds of lives, is completely beyond me, unless the aim was to start a pandemic on purpose. In November of 2019, three technicians at the Wuhan Institute of Virology developed symptoms consistent with a flu-like illness. Anthony Fauci, Peter Daszak, and Ralph Baric knew at once what had happened, because back channels exist between this laboratory and our scientists and officials. December 12th, 2019, Ralph Baric signed a Material Transfer Agreement (essentially, an NDA) to receive Coronavirus mRNA vaccine-related materials co-owned by Moderna and NIH. It wasn’t until a whole month later, on January 11th, 2020, that China allegedly sent us the sequence to what would become known as SARS-CoV-2. Moderna claims, rather absurdly, that they developed a working vaccine from this sequence in under 48 hours. Stephane Bancel, the current CEO of Moderna, was formerly the CEO of bioMerieux, a French multinational corporation specializing in medical diagnostic tech, founded by one Alain Merieux. Alain Merieux was one of the individuals who was instrumental in the construction of the Wuhan Institute of Virology’s P4 lab. The sequence given as the closest relative to SARS-CoV-2, RaTG13, is not a real virus. It is a forgery. It was made by entering a gene sequence by hand into a database, to create a cover story for the existence of SARS-CoV-2, which is very likely a gain-of-function chimera produced at the Wuhan Institute of Virology and was either leaked by accident or intentionally released. The animal reservoir of SARS-CoV-2 has never been found. This is not a conspiracy “theory”. It is an actual criminal conspiracy, in which people connected to the development of Moderna’s mRNA-1273 are directly connected to the Wuhan Institute of Virology and their gain-of-function research by very few degrees of separation, if any. The paper trail is well- established. The lab-leak theory has been suppressed because pulling that thread leads one to inevitably conclude that there is enough circumstantial evidence to link Moderna, the NIH, the WIV, and both the vaccine and the virus’s creation together. In a sane country, this would have immediately led to the world’s biggest RICO and mass murder case. Anthony Fauci, Peter Daszak, Ralph Baric, Shi Zhengli, and Stephane Bancel, and their accomplices, would have been indicted and prosecuted to the fullest extent of the law. Instead, billions of our tax dollars were awarded to the perpetrators. The FBI raided Allure Medical in Shelby Township north of Detroit for billing insurance for “fraudulent COVID-19 cures”. The treatment they were using? Intravenous Vitamin C. An antioxidant. Which, as described above, is an entirely valid treatment for COVID-19-induced sepsis, and indeed, is now part of the MATH+ protocol advanced by Dr. Paul E. Marik. The FDA banned ranitidine (Zantac) due to supposed NDMA (N-nitrosodimethylamine) contamination. Ranitidine is not only an H2 blocker used as antacid, but also has a powerful antioxidant effect, scavenging hydroxyl radicals. This gives it utility in treating COVID-19. The FDA also attempted to take N-acetylcysteine, a harmless amino acid supplement and antioxidant, off the shelves, compelling Amazon to remove it from their online storefront. This leaves us with a chilling question: did the FDA knowingly suppress antioxidants useful for treating COVID-19 sepsis as part of a criminal conspiracy against the American public? The establishment is cooperating with, and facilitating, the worst criminals in human history, and are actively suppressing non-vaccine treatments and therapies in order to compel us to inject these criminals’ products into our bodies. This is absolutely unacceptable. COVID-19 Vaccine Development and Links to Transhumanism: This section deals with some more speculative aspects of the pandemic and the medical and scientific establishment’s reaction to it, as well as the disturbing links between scientists involved in vaccine research and scientists whose work involved merging nanotechnology with living cells. On June 9th, 2020, Charles Lieber, a Harvard nanotechnology researcher with decades of experience, was indicted by the DOJ for fraud. Charles Lieber received millions of dollars in grant money from the US Department of Defense, specifically the military think tanks DARPA, AFOSR, and ONR, as well as NIH and MITRE. His specialty is the use of silicon nanowires in lieu of patch clamp electrodes to monitor and modulate intracellular activity, something he has been working on at Harvard for the past twenty years. He was claimed to have been working on silicon nanowire batteries in China, but none of his colleagues can recall him ever having worked on battery technology in his life; all of his research deals with bionanotechnology, or the blending of nanotech with living cells. The indictment was over his collaboration with the Wuhan University of Technology. He had double- dipped, against the terms of his DOD grants, and taken money from the PRC’s Thousand Talents plan, a program which the Chinese government uses to bribe Western scientists into sharing proprietary R&D information that can be exploited by the PLA for strategic advantage. Charles Lieber’s own papers describe the use of silicon nanowires for brain-computer interfaces, or “neural lace” technology. His papers describe how neurons can endocytose whole silicon nanowires or parts of them, monitoring and even modulating neuronal activity. Charles Lieber was a colleague of Robert Langer. Together, along with Daniel S. Kohane, they worked on a paper describing artificial tissue scaffolds that could be implanted in a human heart to monitor its activity remotely. Robert Langer, an MIT alumnus and expert in nanotech drug delivery, is one of the co-founders of Moderna. His net worth is now $5.1 billion USD thanks to Moderna’s mRNA-1273 vaccine sales. Both Charles Lieber and Robert Langer’s bibliographies describe, essentially, techniques for human enhancement, i.e. transhumanism. Klaus Schwab, the founder of the World Economic Forum and the architect behind the so-called “Great Reset”, has long spoken of the “blending of biology and machinery” in his books. Since these revelations, it has come to the attention of independent researchers that the COVID-19 vaccines may contain reduced graphene oxide nanoparticles. Japanese researchers have also found unexplained contaminants in COVID-19 vaccines. Graphene oxide is an anxiolytic. It has been shown to reduce the anxiety of laboratory mice when injected into their brains. Indeed, given SARS-CoV-2 Spike’s propensity to compromise the blood-brain barrier and increase its permeability, it is the perfect protein for preparing brain tissue for extravasation of nanoparticles from the bloodstream and into the brain. Graphene is also highly conductive and, in some circumstances, paramagnetic. In 2013, under the Obama administration, DARPA launched the BRAIN Initiative; BRAIN is an acronym for Brain Research Through Advancing Innovative Neurotechnologies®. This program involves the development of brain-computer interface technologies for the military, particularly non-invasive, injectable systems that cause minimal damage to brain tissue when removed. Supposedly, this technology would be used for healing wounded soldiers with traumatic brain injuries, the direct brain control of prosthetic limbs, and even new abilities such as controlling drones with one’s mind. Various methods have been proposed for achieving this, including optogenetics, magnetogenetics, ultrasound, implanted electrodes, and transcranial electromagnetic stimulation. In all instances, the goal is to obtain read or read-write capability over neurons, either by stimulating and probing them, or by rendering them especially sensitive to stimulation and probing. However, the notion of the widespread use of BCI technology, such as Elon Musk’s Neuralink device, raises many concerns over privacy and personal autonomy. Reading from neurons is problematic enough on its own. Wireless brain-computer interfaces may interact with current or future wireless GSM infrastructure, creating neurological data security concerns. A hacker or other malicious actor may compromise such networks to obtain people’s brain data, and then exploit it for nefarious purposes. However, a device capable of writing to human neurons, not just reading from them, presents another, even more serious set of ethical concerns. A BCI that is capable of altering the contents of one’s mind for innocuous purposes, such as projecting a heads-up display onto their brain’s visual center or sending audio into one’s auditory cortex, would also theoretically be capable of altering mood and personality, or perhaps even subjugating someone’s very will, rendering them utterly obedient to authority. This technology would be a tyrant’s wet dream. Imagine soldiers who would shoot their own countrymen without hesitation, or helpless serfs who are satisfied to live in literal dog kennels. BCIs could be used to unscrupulously alter perceptions of basic things such as emotions and values, changing people’s thresholds of satiety, happiness, anger, disgust, and so forth. This is not inconsequential. Someone’s entire regime of behaviors could be altered by a BCI, including such things as suppressing their appetite or desire for virtually anything on Maslow’s Hierarchy of Needs. Anything is possible when you have direct access to someone’s brain and its contents. Someone who is obese could be made to feel disgust at the sight of food. Someone who is involuntarily celibate could have their libido disabled so they don’t even desire sex to begin with. Someone who is racist could be forced to feel delight over cohabiting with people of other races. Someone who is violent could be forced to be meek and submissive. These things might sound good to you if you are a tyrant, but to normal people, the idea of personal autonomy being overridden to such a degree is appalling. For the wealthy, neural laces would be an unequaled boon, giving them the opportunity to enhance their intelligence with neuroprosthetics (i.e. an “exocortex”), and to deliver irresistible commands directly into the minds of their BCI-augmented servants, even physically or sexually abusive commands that they would normally refuse. If the vaccine is a method to surreptitiously introduce an injectable BCI into millions of people without their knowledge or consent, then what we are witnessing is the rise of a tyrannical regime unlike anything ever seen before on the face of this planet, one that fully intends to strip every man, woman, and child of our free will. Our flaws are what make us human. A utopia arrived at by removing people’s free will is not a utopia at all. It is a monomaniacal nightmare. Furthermore, the people who rule over us are Dark Triad types who cannot be trusted with such power. Imagine being beaten and sexually assaulted by a wealthy and powerful psychopath and being forced to smile and laugh over it because your neural lace gives you no choice but to obey your master. The Elites are forging ahead with this technology without giving people any room to question the social or ethical ramifications, or to establish regulatory frameworks that ensure that our personal agency and autonomy will not be overridden by these devices. They do this because they secretly dream of a future where they can treat you worse than an animal and you cannot even fight back. If this evil plan is allowed to continue, it will spell the end of humanity as we know it. Conclusions: The current pandemic was produced and perpetuated by the establishment, through the use of a virus engineered in a PLA-connected Chinese biowarfare laboratory, with the aid of American taxpayer dollars and French expertise. This research was conducted under the absolutely ridiculous euphemism of “gain-of-function” research, which is supposedly carried out in order to determine which viruses have the highest potential for zoonotic spillover and preemptively vaccinate or guard against them. Gain-of-function/gain-of-threat research, a.k.a. “Dual-Use Research of Concern”, or DURC, is bioweapon research by another, friendlier-sounding name, simply to avoid the taboo of calling it what it actually is. It has always been bioweapon research. The people who are conducting this research fully understand that they are taking wild pathogens that are not infectious in humans and making them more infectious, often taking grants from military think tanks encouraging them to do so. These virologists conducting this type of research are enemies of their fellow man, like pyromaniac firefighters. GOF research has never protected anyone from any pandemic. In fact, it has now started one, meaning its utility for preventing pandemics is actually negative. It should have been banned globally, and the lunatics performing it should have been put in straitjackets long ago. Either through a leak or an intentional release from the Wuhan Institute of Virology, a deadly SARS strain is now endemic across the globe, after the WHO and CDC and public officials first downplayed the risks, and then intentionally incited a panic and lockdowns that jeopardized people’s health and their livelihoods. This was then used by the utterly depraved and psychopathic aristocratic class who rule over us as an excuse to coerce people into accepting an injected poison which may be a depopulation agent, a mind control/pacification agent in the form of injectable “smart dust”, or both in one. They believe they can get away with this by weaponizing the social stigma of vaccine refusal. They are incorrect. Their motives are clear and obvious to anyone who has been paying attention. These megalomaniacs have raided the pension funds of the free world. Wall Street is insolvent and has had an ongoing liquidity crisis since the end of 2019. The aim now is to exert total, full-spectrum physical, mental, and financial control over humanity before we realize just how badly we’ve been extorted by these maniacs. The pandemic and its response served multiple purposes for the Elite: Concealing a depression brought on by the usurious plunder of our economies conducted by rentier-capitalists and absentee owners who produce absolutely nothing of any value to society whatsoever. Instead of us having a very predictable Occupy Wall Street Part II, the Elites and their stooges got to stand up on television and paint themselves as wise and all-powerful saviors instead of the marauding cabal of despicable land pirates that they are. Destroying small businesses and eroding the middle class. Transferring trillions of dollars of wealth from the American public and into the pockets of billionaires and special interests. Engaging in insider trading, buying stock in biotech companies and shorting brick-and-mortar businesses and travel companies, with the aim of collapsing face-to-face commerce and tourism and replacing it with e-commerce and servitization. Creating a casus belli for war with China, encouraging us to attack them, wasting American lives and treasure and driving us to the brink of nuclear armageddon. Establishing technological and biosecurity frameworks for population control and technocratic- socialist “smart cities” where everyone’s movements are despotically tracked, all in anticipation of widespread automation, joblessness, and food shortages, by using the false guise of a vaccine to compel cooperation. Any one of these things would constitute a vicious rape of Western society. Taken together, they beggar belief; they are a complete inversion of our most treasured values. What is the purpose of all of this? One can only speculate as to the perpetrators’ motives, however, we have some theories. The Elites are trying to pull up the ladder, erase upward mobility for large segments of the population, cull political opponents and other “undesirables”, and put the remainder of humanity on a tight leash, rationing our access to certain goods and services that they have deemed “high-impact”, such as automobile use, tourism, meat consumption, and so on. Naturally, they will continue to have their own luxuries, as part of a strict caste system akin to feudalism. Why are they doing this? Simple. The Elites are Neo-Malthusians and believe that we are overpopulated and that resource depletion will collapse civilization in a matter of a few short decades. They are not necessarily incorrect in this belief. We are overpopulated, and we are consuming too many resources. However, orchestrating such a gruesome and murderous power grab in response to a looming crisis demonstrates that they have nothing but the utmost contempt for their fellow man. To those who are participating in this disgusting farce without any understanding of what they are doing, we have one word for you. Stop. You are causing irreparable harm to your country and to your fellow citizens. To those who may be reading this warning and have full knowledge and understanding of what they are doing and how it will unjustly harm millions of innocent people, we have a few more words. Damn you to hell. You will not destroy America and the Free World, and you will not have your New World Order. We will make certain of that. *  *  * This PDF document contains 14 pages, followed by another 17 pages of references. For those, please visit the original PDF file at Covid19 – The Spartacus Letter. *  *  * We try to run the Automatic Earth on donations. Since ad revenue has collapsed, you are now not just a reader, but an integral part of the process that builds this site. Thank you for your support. Support the Automatic Earth in virustime. Donate with Paypal, Bitcoin and Patreon. Tyler Durden Mon, 09/27/2021 - 00:00.....»»

Category: dealsSource: nyt3 hr. 8 min. ago

Goldman Raises Year-End Oil Price Target To $90

Goldman Raises Year-End Oil Price Target To $90 Just days after Goldman's head commodity analyst Jeff Currie told Bloomberg TV that the bank anticipates oil spiking to $90 if the winter is colder than usual, on Sunday afternoon Goldman went ahead and made that its base case and in a note from energy strategist Damien Courvalin, he writes that with Brent prices reaching new highs since October 2018, the bank now forecasts that this rally will continue, "with our year-end Brent forecast of $90/bbl vs. $80/bbl previously." What tipped the scales is that while Goldman has long held a bullish oil view, "the current global oil supply-demand deficit is larger than we expected, with the recovery in global demand from the Delta impact even faster than our above consensus forecast and with global supply remaining short of our below consensus forecasts." Among the supply factors cited by Goldman is hurricane Ida - the "most bullish hurricane in US history" - which more than offset the ramp-up in OPEC+ production since July with non-OPEC+ non-shale production continuing to disappoint. Meanwhile, as noted above, on the demand side Goldman cited low hospitalization rates which are leading more countries to re-open, including to international travel in particularly COVID-averse countries in Asia. Finally, from a seasonal standpoint, Courvalin sees winter demand risks as "further now squarely skewed to the upside" as the global gas shortage will increase oil fired power generation. From a fundamental standpoint, the current c.4.5 mb/d observable inventory draws are the largest on record, including for global SPRs and oil on water, and follow the longest deficit on record, started in June 2020. For the oil bears, Goldman does not see this deficit as reversing in coming months as its scale will overwhelm both the willingness and ability for OPEC+ to ramp up, with the shale supply response just starting. This sets the stage for inventories to fall to their lowest level since 2013 by year-end (after adjusting for pipeline fill), supporting further backwardation in the oil forward curve where positioning remains low. But what about a production response? While Goldman does expect short-cycle production to respond by 2022 at the bank's higher price forecast, from core-OPEC, Russia and shale, this according to Goldman, will only lay bare the structural nature of the oil market repricing. To be sure, there will likely be a time to be tactically bearish in 2022, especially if a US-Iran deal is eventually reached. The bank's base-case assumption is for such an agreement to be reached in April, leading the bank to then trim its price target to an $80/bbl price forecast in 2Q22-4Q22 (vs. its 4Q21-1Q22 $85/bbl quarterly average forecast). This would, however, remain a tactical call and a likely timespread trade according to Courvalin, with long-dated oil prices poised to reset higher from current levels, especially as the hedging momentum shifts from US producer selling to airline buying (a move which Goldman says to position for with a long Dec-22 Brent and short Dec-22 Brent put trade recommendations).   Meanwhile, the lack of long-cycle capex response - here you can thank the green crazy sweeping the world - the quickly diminishing OPEC spare capacity (Goldman expects normalization by early 2022), the inability for shale producers to sustain production growth (given their low reinvestment rate targets) and oil service and carbon cost inflation will all instead point to the need for sustainably higher long-dated oil prices. Remarkably, Goldman now expects the market to return to a structural deficit by 2H23, which leads it to raise its 2023 oil price forecast from $65/bbl to $85/bbl, and the mid-cycle valuation oil price used by Goldman's equity analysts to $70/bbl. Translation: expect a slew of price hikes on energy stocks in the coming days from Goldman. Finally, where could Goldman's forecast - which would infuriate the white house as gasoline prices are about to explode higher - be wrong? For what it's worth, the bank sees the greatest risk on the timeline of its bullish view. On the demand side, it would take a potentially new variant that renders vaccine ineffective. Beyond that, however, the bank expects limited downside risk from China, with its economists not expecting a hard landing and with our demand growth forecast driven by DMs and other EMs instead. This leaves near-term risks having to come from the supply side, most notably OPEC+, which next meets on October 4. And while an aggressively faster ramp-up in production by year-end would soften (but not derail) our projected deficit, it would only further delay the shale rebound, which would reinforce the structural nature of the next rally given binding under-investment in oil services by 2023. In addition, a large ramp-up in OPEC+ production would simply fast-forward the decline in global spare capacity to historically low levels, replacing a cyclical tight market with a structural one. The full report as usual available to pro subscribers in the usual place. Tyler Durden Sun, 09/26/2021 - 20:36.....»»

Category: dealsSource: nyt7 hr. 8 min. ago

Top 10 NFT Projects By Weekly Sales Volume: Axie Remains On Top, Cupcats, Lazy Lions Top Gainers

The non-fungible token market continues to heat up and is seeing record sales volume on platforms like OpenSea, an NFT marketplace for buying and selling items. read more.....»»

Category: blogSource: benzinga11 hr. 8 min. ago

Dozens of cargo ships stuck waiting off New York"s coast amid port staff shortages and surging demand for goods

Increased demand for goods, coupled with the labor shortage is causing shipping disruptions in New York, following similar problems in California. As of 9 p.m. local time Saturday, the ships appear to have been stuck in place for hours, The Daily Mail reported. Photo by Michael Nagle/Xinhua via Getty Images Dozens of container ships are stuck off the coast of New York, per Mail Online. It comes amid surging demand for goods ahead of the holiday season and a national labor shortage. Port of New York and New Jersey appears to be facing similar issues as West coast ports. See more stories on Insider's business page. Around 24 cargo ships and oil tankers are stuck waiting to dock off the coast of Long Island, New York, due to a surge in demand for consumer goods and short-staffed ports.MarineTraffic, the global ship tracking site, showed ships gathered a few miles off the coastline that stretches from Long Beach in the west to Lido Beach and Jones Beach Island in the east, The Daily Mail reported.The ships appeared to have been stuck in place since at least Saturday evening, the outlet added.Pandemic-induced shopping sprees ahead of the holiday season, coupled with a national labor shortage, are thought to be the main cause.Similar issues have been occurring on the West coast in recent weeks. Insider previously reported that 56 container ships were stuck at anchor or in drift areas off of Los Angeles and Long Beach ports.Those ports were dealing with 140 ships, including 87 freighters, according to Insider's report.According to the Container News website, the Port of New York and New Jersey serves the world's major ocean carriers and global alliances and consists of a complex of approximately 386 km of shipping channels, as well as anchorages, and port facilities.With record numbers of huge cargo ships clogging key ports, causing a knock-on effect on the global supply chain, many retailers are being forced to find creative ways to overcome shortages and price hikes, Insider previously reported. Read the original article on Business Insider.....»»

Category: worldSource: nyt21 hr. 24 min. ago

What to know about futures contracts - and the 5 reasons why investors trade them

Futures are contracts that allow buyers and sellers to agree on the price and delivery of an asset. These contracts can help lock-in prices and mitigate unexpected costs. Companies also use futures contracts to hedge and mitigate the risk of unexpected changes in prices. Thomas Barwick/Getty Images Futures are financial contracts that investors can use to speculate on the direction that certain assets will move. Futures contracts can derive their value from several different asset types like commodities, currencies, stock indexes, and agricultural items. Investing in the futures market is considered highly speculative because of their low margin requirements and volatility. Visit Insider's Investing Reference library for more stories. Much of the investing landscape is based on how an investor feels about the economic landscape and the ways in which that investor can profit or protect themselves. If you believe in a company's ability to succeed, perhaps you might buy the stock or a call option.If you're pessimistic about a company's outlook, you may consider put options. A futures contract is another financial tool that traders can use to speculate on the price swings of assets like oil, gold and other commodities.But what exactly are futures, how do they work, and what sets them apart from options?What are futures?Futures are contracts where the buyer agrees to buy a commodity or financial instrument a particular the quantity, price, and date at a later point in time - and the seller agrees to sell or deliver the asset. Futures are derivatives, which means that their value is derived from an underlying asset. For example, a futures contract on crude oil will be heavily influenced by the price fluctuations of the oil market. Futures contracts can be critical for businesses that depend on certain input goods to operate. The airline industry is well-known for this, because of the fluctuating prices for jet fuel, and uses futures contracts to lock in prices and protect against unexpected costs. While futures contracts based on commodities like corn, oil, and wheat are the most common, there are several other asset types that a futures contract can derive its value from. Here's a short list: Commodity futures: Commodities are tangible assets, agricultural products, and natural resources used in commerce and trade. A short list of futures in this category would include soybeans, corn, wheat, crude oil, and natural gas.Precious metal futures: Gold and silver are the most common metals that fall into this category. Investors who purchase futures contracts on gold or silver are usually looking to hedge against global financial uncertainty, inflation, or geopolitical events. Stock index futures: Futures contracts can also derive their value from an index like the S&P 500, Nasdaq, Russell 2000, or Dow Jones. Investors use stock index futures to capitalize on anticipated movements in an index and can be sensitive to events like data releases, such as the US jobs report or statements by the Federal Reserve. Currency futures: These types of futures contracts can be based on the exchange rates between countries. Some of the most popular currency futures contracts include the Canadian dollar, British Pound, Japanese Yen, and Euro. US Treasury futures: The interest rates on Treasury bonds have a significant impact on a large part of the financial markets. US Treasury Futures allow investors to speculate on the potential changes in interest rates. Quick tip: Treasury futures are not available for every type of treasury bond. Only 2-, 5-, 10-, and 30-year bonds are used for futures contracts. Understanding how futures workThere are five key parts to every futures contract, also known as standard contract specifications. Trading hours: Unlike the US stock market, which is open from 9:30 a.m. to 4 p.m. ET, futures trade almost 24 hours a day, six days a week, starting on Sunday at 6 p.m. ET. The closing time varies between 5 p.m. and 6:45 p.m. ET on Friday, depending on the type of contract you're trading. Contract size: Each type of contract has a predetermined size. One contract of gold will always equal 1,000 troy ounces - a unit of measure used for weighing precious metals - while one contract of S&P 500 futures will be $50 times the S&P 500 index. (So, for example, if the S&P 500 is trading at 2,300, the value of the contract would be $115,000 [$50 x 2,300]).Contract value: The contract value is the current price of the contract. If gold is trading at $1,500 per ounce today, then the contract value would be $150,000. Tick size: This is the smallest denomination that a contract can fluctuate and varies depending on the type of contract. Delivery method: Futures contracts can be financially settled or physically settled. From the investor's perspective, these are usually financially settled, whereas businesses may choose physically settled contracts. Quick tip: Some brokerages do not allow for physically settled futures contracts and will close the contract on your behalf if you do not do it manually. This protects the investor from receiving large quantities of unwanted items. Futures contracts can be purchased on margin, meaning that an investor only needs to put in a small amount of money to control a much larger sum in the market. The minimum amount of money required to enter into a futures contract is known as the initial margin requirement.These requirements are set by the futures exchange and are subject to change. Generally, the margin requirement for futures contracts is between 3-12%. This means, depending on the price of the contract, an investor could spend $5,000 of their own cash to control a $100,000 investment, which represents only 5%.This amount of leverage can present serious risks if the investment does not go as planned and in some cases could cause an investor to lose more than the initial amount invested. Quick tip: Micro E-mini index futures began trading in 2019. This allows investors to enter into futures contracts on a stock index at a much lower price point. These micro futures are 1/10th the size of the standard index futures. 5 reasons investors trade futures Diversifying: Adding futures to your investment portfolio can help you gain exposure to different types of asset classes that aren't as widely available in the stock, bond, and options markets. Speculating: Investors who have an appetite for speculation may see significant gains (or losses) much quicker than in other markets. Hedging: Companies use futures contracts to mitigate the risk of unexpected changes in price. "This works particularly well for anyone that needs to control input prices for a product," says Dominique Henderson, Certified Financial Planner and owner of DJH Capital Management. If prices are rapidly increasing for a commodity, a futures contract can lock in current prices and help preserve profits. Earning tax benefits: Some futures trades can qualify for preferential tax rates using the 60/40 rule: 60% of the profits will receive long-term capital gains treatment, and the remaining 40% will be treated with short-term capital gains. This is a unique structure compared to short- and long-term gains with stocks. Short selling: Short selling is the process of profiting from downward movements in the market. For stocks, short selling usually has higher margin requirements than long positions. But with futures, the margin requirement is the same for both long positions and short positions. This means that the investor can risk less of their cash on-hand for short selling positions with futures than with stocks. Pros and cons of futures As with any investment vehicle, there are pros and cons that you should be aware of. These are some of the major advantages and disadvantages.ProsConsMay qualify for special tax treatment Generally low margin requirements Longer investing hours compared to the stock marketHighly leveraged, meaning the investor could lose more than their initial investment Highly speculative with the potential for significant losses Increased complexityFutures vs. optionsFutures and stock options have many similarities - both are contracts between two parties and can allow an investor to hedge and protect their portfolio - but there are some key differences that you should be aware of. FuturesStock optionsBuyer has the obligation to purchase, while the seller has the obligation to sell the underlying assetCannot be purchased on individual stocks, only certain stock indexesCan lock in the prices for physical goods and financial instrumentsBuyer has the right, not the obligation, to buy or sell shares at the specified price Can be purchased on nearly any individual stock or ETF Options can only lock in prices for financial instruments, not physical goodsThe financial takeawayInvesting with futures can be a way to diversify your portfolio in ways that the more traditional stock and bond investor can't. This additional exposure comes with a few trade offs which include higher rates of volatility, longer trading hours, and special tax advantages."Futures tend to be a more complex or advanced financial instrument," adds Henderson. While the potential for large profits may be tempting, carefully consider the risks before entering into futures trading. It may also be wise to consult a Certified Financial Planner to ensure that a negative move in the futures market does not threaten your overall financial security.How to hedge against inflation with investments that keep pace with rising pricesWhat is OTC? A beginner's guide to over-the-counter markets, and the risks and rewards of investing outside the major stock exchangesAlternative investments are exotic assets that can diversify your portfolioTrading and investing are two approaches to playing the stock market that bring their own benefits and risksRead the original article on Business Insider.....»»

Category: topSource: businessinsiderSep 24th, 2021

Before They Were An Inconvenience, But Now The Shortages Are Really Beginning To Sting

Before They Were An Inconvenience, But Now The Shortages Are Really Beginning To Sting Authored by Michael Snyder via TheMostImportantNews.com, Have you noticed that store shelves are starting to get emptier and emptier?  During the panic shopping that was sparked by the start of the COVID pandemic in 2020, there were very intense shortages of certain items, but those shortages did not last very long at all.  But now there are widespread shortages in just about every sector of our economy, and they are starting to become quite painful.  Unfortunately, we are being told to expect the shortages to intensify as we head into the holiday season.  That is extremely alarming, because in many areas the shortages are already quite severe. I had been away from the news for a couple of days, and when I came back there were lots more stories about our ongoing shortages.  For example, the following comes from an excellent piece by Matt Stoller… There are shortages in everything from ocean shipping containers to chlorine tablets to railroad capacity to black pipe (the piping that houses wires inside buildings) to spicy chicken breasts to specialized plastic bags necessary for making vaccines. Moreover, prices for all sorts of items, from housing to food, are changing in weird ways. Beef, for instance, is at near record highs for consumers, but cattle ranchers are getting paid much less than they used to for their cows. In my entire life, I have never seen anything like this. Even the Federal Reserve is admitting that we have a major problem at this point.  In fact, in the latest Beige Book the Fed referred to the shortages a whopping 80 times. In certain parts of the country, these shortages are really beginning to sting.  A reader just emailed me about what is going on in his section of Connecticut, and he said that I could share this with all of you… I am just a regular guy in Connecticut, who has been watching things very closely, especially from a Biblical perspective. I wanted to quickly share with you an experience my wife and I had about two weeks ago at a medium-size, family run grocery store near Waterbury, CT. Seemingly overnight, we noticed there were little yellow signs on the shelves, where certain SKUs used to be. Not entire lines, but individual SKUs. For example, a flavor of oatmeal, certain cereals, etc. The signs said something to the effect of: “This item is no longer available due to supply chain constraints”. I would say there were a few hundred signs in total throughout the store. It wasn’t until we got to the juice/water aisle that we noticed the larger problem: there was no Gatorade (?) and no bottled water (gallon jugs). I have befriended the manager over the years, so I asked him where the water is, and he told me “…they only will give us so many bottles”. I asked who ‘they’ is, and he said the manufacturer: they were being rationed. As he said this, a truck driver happened to walk by and joined in on the conversation. He told us that he just got back from Maine, after a three-day trip- a trip that normally takes him a few hours. He said he, and all of the other truck drivers, sit at the warehouses for days, waiting for their trucks to be filled. To be clear, I asked him how long it normally takes, and he said a few hours at the most. On our way out, I remembered that we needed dog food, so we went to the pet aisle, and there was no cat litter, and no dog food, save a few little bags of the cheapest stuff. All of the things Steve Quayle has been saying about food and water shortages suddenly became reality. I always believed him, but now I was seeing it, at the very local level. We then decided to go to PetSmart to get the dog food. Empty. The entire dog food shelf was empty except for a few bags! Are similar things happening in your part of the country? If so, please feel free to email me and let me know. We need to share intel with one another, because the mainstream media is not telling us the truth. Of course the shortages would not be as severe if we could actually unload all of the container ships that are backlogged at our ports.  Right now, dozens of container ships are sitting along the west coast waiting to be unloaded… The number of container ships at anchor or drifting in San Pedro Bay off the ports of Los Angeles and Long Beach has blown through all previous records. The latest peak: There were an all-time-high 73 container ships in the queue in San Pedro Bay on Sunday, according to the Marine Exchange of Southern California (the tally inched back to 69 on Tuesday). Of the ships offshore Sunday, 36 were forced to drift because anchorages were full. Theoretically, the numbers — already surreally high — could go even higher than this. While designated anchorages are limited, the space for ships to safely drift offshore is not. This is the same problem that I talked about the other day. At one time we had more able-bodied workers than we knew what to do with, but now there is an extreme shortage of workers all over the globe. Sadly, it has gotten to a point where we don’t even have enough people to drive our kids to school… School districts around the country are struggling to fill thousands of bus driver positions as worker shortages lead to late arrivals and last-minute scrambles to bring retired workers back onto payrolls. The shortages are so bad in some places that districts are taking extraordinary steps to get kids to school as students return to in-person classes this fall. Philadelphia’s school district will pay families $300 a month, or $3,000 for the year, to opt out of transportation services and get their kids to school on their own. Albemarle County Public Schools in Virginia is offering a $2,500 bonus to new drivers — $100 more than the school district in the county seat, Charlottesville, is offering. This is the worst labor shortage that the U.S. has ever faced, and it just keeps getting worse. So where did all the people go? Without enough able-bodied workers, our economy is experiencing a whole host of difficulties right now.  And when you consider everything else that has been going on, it shouldn’t be a surprise that Joe Biden’s approval rating just sunk to a new record low… Eight months after President Joe Biden’s inauguration, his job approval rating has fallen six percentage points to 43%, the lowest of his presidency. For the first time, a majority, 53%, now disapproves of Biden’s performance. These findings are from a Sept. 1-17 Gallup poll that was conducted after the U.S. military evacuated more than 120,000 people from Afghanistan. The United States’ exit from the nation’s longest war was marred by the Taliban’s quick takeover of most of the country and a suicide bombing at the airport in Kabul, which killed 13 U.S. service members. Over the same period, COVID-19 infection rates, nationally, were surging, leading to hospital overflows in some regions. And there are some parts of the nation where his approval rating is absolutely disastrous.  Just check out the latest numbers from Iowa… Just 31% of Iowans approved of how Joe Biden is handling his duties as president while a whopping 62% disapprove. Biden’s disapproval number is below the lowest ever measured by ace pollster J. Ann Selzer for former presidents Donald Trump (35%) and Barack Obama (36%). “This is a bad poll for Joe Biden, and it’s playing out in everything that he touches right now,” Selzer told the Des Moines Register. Less than a year ago, a lot of Americans were viewing Biden as some sort of a “savior” figure. That didn’t exactly work out, did it? Many of us have been warning that shortages and high levels of inflation were coming for a very long time, but of course most of the population is not interested in such warnings. They just want to be told that everything is going to be okay. But the truth is that everything is not going to be okay, and the pain that we have experienced so far is just the beginning. *  *  * It is finally here! Michael’s new book entitled “7 Year Apocalypse” is now available in paperback and for the Kindle on Amazon. Tyler Durden Fri, 09/24/2021 - 15:20.....»»

Category: blogSource: zerohedgeSep 24th, 2021

Making Sense of the Q3 Earnings Picture and Beyond

Recent updates on the revisions trends have been somewhat disconcerting, as you can see in the chart below that tracks the evolution of Q3 earnings growth expectations... One enduring feature of the corporate earnings landscape that unfolded following the initial Covid-related disruptions has been the steady improvement in estimates. The favorable revisions trend got underway in July 2020 and gained pace in the following quarters.However, recent updates on the revisions trends have been somewhat disconcerting, as you can see in the chart below that tracks the evolution of Q3 earnings growth expectations.Image Source: Zacks Investment ResearchWhat we see here is that the trend appears to have shifted course over the last few weeks after remaining modestly positive since the start of the quarter. This loss of momentum is likely tied to the emerging economic slowdown, which in turn is likely a function of the Delta variant. Estimates of GDP growth have been steadily coming down and currently stand around +3%, roughly half of the growth rate expected a few months back.We also need to keep an eye on the margins outlook, given rising cost trends in labor, inputs, freight/logistics and other line items.That said, the market appears to agree with the Fed’s assessment of this trend as ‘transitory’ and a function of Covid-related disruptions that will eventually even out. This view is reflected in current consensus estimates, as you can see in the chart below.Image Source: Zacks Investment ResearchThis ‘transitory’ view of the ongoing cost pressures is even more pronounced in the annual view of the margins picture, as the chart below shows.Image Source: Zacks Investment ResearchWe all know that the ‘transitory’ or otherwise debate has implications for Fed policy, which is as important for the market as the outlook for earnings and margins.To bring the conversation back to the revisions trend, it is important to point out that estimates for 2021 Q4 have nudged up in recent weeks even as Q3 has stalled out.Expectations for Q3 & Beyond The last earnings season (2021 Q2) not only witnessed a very high earnings growth rate, but the aggregate tally of total earnings also reached a new all-time quarterly record, surpassing the record set in the preceding period. Other positives that came out of the Q2 earnings season included the breadth of strength across all the key sectors and the notable momentum on the revenue front.We know that the unusually high growth rates of the first two quarters will not continue in the last two quarters as they largely reflected easy comparisons to the year-earlier periods that were severely impacted by Covid-related disruptions. Comparisons will be relatively normal in 2021 Q3 and beyond as the U.S. economy had started opening up in the year-earlier period and hence the expected deceleration in the growth pace.You can see this expected growth deceleration in the below chart that puts 2021 Q3 earnings and revenue growth expectations in the context of where growth has been in the preceding four periods and the estimates for the following three quarters.Image Source: Zacks Investment ResearchThe comparable picture on an annual basis is no less impressive, as you can see in the chart below.Image Source: Zacks Investment ResearchWe mentioned earlier how the aggregate 2021 Q2 earnings tally represented a new all-time quarterly record. You can see that in the chart below, with this year’s four quarters highlighted.Image Source: Zacks Investment ResearchWe all know that large segments of the economy, particularly in the broader leisure, travel and hospitality spaces are held down by the pandemic, with companies in these areas still earning significantly less than they did in the pre-Covid period. In fact, many of these companies aren’t expected to get back to pre-Covid profitability levels for almost one more year.The impressive feature of the record earnings in each of the last two quarters is that they were achieved without help from these key parts of the economy.Earnings Season Gets UnderwayMost companies have fiscal quarters that correspond with the calendar periods. As such, the wide majority of Q3 earnings reports will be from companies that have fiscal quarters ending in September. But there are some companies that have fiscal quarters ending in August and a number of them have been reporting their fiscal August-quarter results in recent days.The earnings releases in recent days from the likes of FedEx FDX, Oracle ORCL, Adobe ADBE, Nike NKE and others all fall in this category; they all had fiscal quarters ending in August. We count all of these reports as part of our Q3 earnings tally.Through Friday, September 24th, we have seen such Q3 results from 10 S&P 500 members, with 6 other index members on deck to report results this week. Operators such as Micron MU, Cintas CTAS, McCormick & Company MCK and others will release their fiscal August quarter results this week.By the time JPMorgan JPM and other big banks start rereporting their September-quarter results on October 13th, we will have seen such August-quarter results from almost two dozen S&P 500 members.For the 10 index members that have reported Q3 results already, total earnings are up +15% from the same period last year on +16% higher revenues, with 90% beating EPS estimates and 50% beating revenue estimates. The proportion of these 10 index members beating both EPS and revenue estimates is 40%.This is too early and the sample size is too small to offer us any interpretive guidance, but I will be closely monitoring how the revenue beats percentage unfolds in the coming days.That said, the way it looks at present (50% for Q3, below the preceding quarter’s 100% for these 10 index members and only modestly above the 5-year low of 40%) isn’t reassuring.Image Source: Zacks Investment ResearchFor a detailed look at the overall earnings picture, including expectations for the coming periods, please check out our weekly Earnings Trends report >>>>What Will Q3 Earnings Season Show? Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report JPMorgan Chase & Co. (JPM): Free Stock Analysis Report NIKE, Inc. (NKE): Free Stock Analysis Report Micron Technology, Inc. (MU): Free Stock Analysis Report McKesson Corporation (MCK): Free Stock Analysis Report Cintas Corporation (CTAS): Free Stock Analysis Report Oracle Corporation (ORCL): Free Stock Analysis Report Adobe Inc. (ADBE): Free Stock Analysis Report FedEx Corporation (FDX): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 24th, 2021

Is the Dividend Hike Enough to Help APA Turn Attractive?

APA's dividend hike comes after the upstream operator repurchased $1.7 billion in debt via an upsized tender offer in August, which allowed it to considerably lower its annual interest expense. APA Corporation APA recently got approval from the board of directors to increase the quarterly dividend by 3.75 cents to 6.25 cents per share. The new payout will be made on Nov 22 to its common shareholders of record on Oct 22.APA management sees the dividend hike as the beginning of its path to return ‘a higher percentage of cash flow’ to its investors. This comes after the upstream operator opportunistically brought back its debt to improve its financial position. In August, APA repurchased $1.7 billion in debt via an upsized tender offer, which allowed the company to reduce its annual interest expense by 20%, or approximately $78 million — more than enough to take care of its annual dividend obligation of $57 million.At its September investor update earlier in the month, APA said that it is on track to generate $1.6-$1.7 billion in upstream free cash flow for the full year, assuming the current strip prices for the second half of 2021. This, together with the company’s aggressive cost management initiatives, should help in its debt reduction goal and achieve its leverage target of less than 1.5 times debt-to-EBITDA. Meanwhile, APA’s annual investment requirement will be some $1.2 billion.APA’s Suriname portfolio is particularly exciting, where it continues to achieve significant drilling success with four discoveries since January 2020. The company has partnered with TotalEnergies TTE in this region, which lies off the north coast of South America. Over time, Suriname is expected to become one of APA’s major assets with significant cash flow potential.All of this sets it up well for the long-term sustainability of APA’s free cash flow generating capacity and future increases in dividend. But one thing that may concern potential investors is that even with the 150% hike this quarter, APA’s annual dividend of 25 cents per share yields 1.16%, which is still low.It compares unfavorably to the 1.57% and1.34% yields offered by peers Marathon Oil MRO and Hess HES, respectively. Meanwhile, the S&P’s dividend yield is around 1.3% and therefore APA’s payout is not enough to attract dividend-oriented investors. This is probably the primary reason behind the company’s Zacks Rank #3 (Hold) and its relative underperformance to the industry year to date (+51.8% versus +78.9%).You can see the complete list of today’s Zacks #1 Rank stocks here. Image Source: Zacks Investment ResearchWe believe that sustained periods of higher oil and gas prices might help APA to achieve its long-term target of increasing its base dividend yield to a level in line with or above the S&P 500. That in turn might help the stock to catch up. Time to Invest in Legal Marijuana If you’re looking for big gains, there couldn’t be a better time to get in on a young industry primed to skyrocket from $17.7 billion back in 2019 to an expected $73.6 billion by 2027. After a clean sweep of 6 election referendums in 5 states, pot is now legal in 36 states plus D.C. Federal legalization is expected soon and that could be a still greater bonanza for investors. Even before the latest wave of legalization, Zacks Investment Research has recommended pot stocks that have shot up as high as +285.9%. You’re invited to check out Zacks’ Marijuana Moneymakers: An Investor’s Guide. It features a timely Watch List of pot stocks and ETFs with exceptional growth potential.Today, Download Marijuana Moneymakers FREE >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Marathon Oil Corporation (MRO): Free Stock Analysis Report APA Corporation (APA): Free Stock Analysis Report Hess Corporation (HES): Free Stock Analysis Report TotalEnergies SE Sponsored ADR (TTE): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 24th, 2021

AAR (AIR) Q1 Earnings and Revenues Surpass Estimates

AAR (AIR) delivered earnings and revenue surprises of 6.12% and 3.99%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock? AAR (AIR) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 6.12%. A quarter ago, it was expected that this airplane maintenance company would post earnings of $0.44 per share when it actually produced earnings of $0.47, delivering a surprise of 6.82%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.AAR, which belongs to the Zacks Aerospace - Defense Equipment industry, posted revenues of $455.1 million for the quarter ended August 2021, surpassing the Zacks Consensus Estimate by 3.99%. This compares to year-ago revenues of $400.8 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.AAR shares have lost about 10.7% since the beginning of the year versus the S&P 500's gain of 17%.What's Next for AAR?While AAR has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for AAR was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.59 on $467.45 million in revenues for the coming quarter and $2.62 on $1.94 billion in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Aerospace - Defense Equipment is currently in the top 49% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AAR Corp. (AIR): Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment Research.....»»

Category: topSource: zacksSep 23rd, 2021

CalAmp (CAMP) Q2 Earnings Surpass Estimates

CalAmp (CAMP) delivered earnings and revenue surprises of 33.33% and -0.95%, respectively, for the quarter ended August 2021. Do the numbers hold clues to what lies ahead for the stock? CalAmp (CAMP) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 33.33%. A quarter ago, it was expected that this wireless communications company would post earnings of $0.07 per share when it actually produced earnings of $0.08, delivering a surprise of 14.29%.Over the last four quarters, the company has surpassed consensus EPS estimates four times.CalAmp, which belongs to the Zacks Electronics - Miscellaneous Components industry, posted revenues of $79.01 million for the quarter ended August 2021, missing the Zacks Consensus Estimate by 0.95%. This compares to year-ago revenues of $83.54 million. The company has topped consensus revenue estimates two times over the last four quarters.The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.CalAmp shares have added about 1.3% since the beginning of the year versus the S&P 500's gain of 17%.What's Next for CalAmp?While CalAmp has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.Ahead of this earnings release, the estimate revisions trend for CalAmp was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $0.14 on $84.23 million in revenues for the coming quarter and $0.45 on $332.04 million in revenues for the current fiscal year.Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Electronics - Miscellaneous Components is currently in the top 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. More Stock News: This Is Bigger than the iPhone! It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.Click here for the 4 trades >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CalAmp Corp. (CAMP): Free Stock Analysis Report To read this article on Zacks.com click here......»»

Category: topSource: zacksSep 23rd, 2021